As of 2026-04-03, the EV/EBITDA ratio of Spero Therapeutics Inc (SPRO) is -1.96. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SPRO's latest enterprise value is 88.29 mil USD. SPRO's TTM EBITDA according to its financial statements is -44.99 mil USD. Dividing these 2 quantities gives us the above SPRO EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.2x - 15.2x | 14.3x |
| Forward P/E multiples | 15.7x - 20.1x | 18.0x |
| Fair Price | (11.66) - (11.29) | (12.05) |
| Upside | -579.7% - -564.6% | -596.0% |
| Date | EV/EBITDA |
| 2026-04-01 | -1.97 |
| 2026-03-31 | -1.85 |
| 2026-03-30 | -1.72 |
| 2026-03-27 | -1.84 |
| 2026-03-26 | -1.89 |
| 2026-03-25 | -1.94 |
| 2026-03-24 | -1.89 |
| 2026-03-23 | -1.86 |
| 2026-03-20 | -1.89 |
| 2026-03-19 | -2.01 |
| 2026-03-18 | -2.00 |
| 2026-03-17 | -2.15 |
| 2026-03-16 | -2.16 |
| 2026-03-13 | -2.15 |
| 2026-03-12 | -2.16 |
| 2026-03-11 | -2.16 |
| 2026-03-10 | -1.99 |
| 2026-03-09 | -1.82 |
| 2026-03-06 | -1.80 |
| 2026-03-05 | -1.79 |
| 2026-03-04 | -1.79 |
| 2026-03-03 | -1.66 |
| 2026-03-02 | -1.66 |
| 2026-02-27 | -1.64 |
| 2026-02-26 | -1.69 |
| 2026-02-25 | -1.70 |
| 2026-02-24 | -1.71 |
| 2026-02-23 | -1.72 |
| 2026-02-20 | -1.80 |
| 2026-02-19 | -1.92 |
| 2026-02-18 | -1.84 |
| 2026-02-17 | -1.86 |
| 2026-02-13 | -1.91 |
| 2026-02-12 | -1.90 |
| 2026-02-11 | -1.89 |
| 2026-02-10 | -1.87 |
| 2026-02-09 | -1.87 |
| 2026-02-06 | -1.95 |
| 2026-02-05 | -1.80 |
| 2026-02-04 | -1.79 |
| 2026-02-03 | -1.60 |
| 2026-02-02 | -1.71 |
| 2026-01-30 | -1.66 |
| 2026-01-29 | -1.74 |
| 2026-01-28 | -1.71 |
| 2026-01-27 | -1.89 |
| 2026-01-26 | -1.99 |
| 2026-01-23 | -1.98 |
| 2026-01-22 | -1.99 |
| 2026-01-21 | -1.87 |